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INTRODUCTION & AIM 
 
Microcontainers have been proposed as a novel approach to 
improve the oral bioavailability of drugs1. Microcontainers are 
small polymeric cylinders on a flat base (Fig. 1). The 
microcontainers allow for protecting the drug in the harsh 
environment of the stomach and also provide the possibility of 
unidirectional release of the drug directly to the small intestinal 
epithelium (Fig. 2).  
 
 
 
Fig. 1: Image of a  
polymeric  
microcontainer     
 
AIM: To investigate the in situ interaction between the 
microcontainers and the small intestinal membrane and to 
evaluate the in vivo performance of the microcontainers filled 
with amorphous sodium salt of furosemide (ASSF) after oral 
dosing to rats (Fig. 3).  
 
Fig. 2: Illustration showing the microcontainer concept 
including the unidirectional release      
 
Fig. 3: Illustrations of the experimental methods. A) Fabrication of SU-8 microcontainers. 
B) Filling with drug powder (amorphous furosemide  sodium salt). C) Spray coating of a 
lid of Eudragit® L100 or chitosan. D) In situ intestinal perfusion studies and oral 
bioavailability studies in rats of the drug-filled microcontainers coated with Eudragit® 
L100 
METHODOLOGY 
Fabrication of microcontainers 
 
Fig. 5: SU-8 
microcontainers  
on a silicon wafer  
SU-8 (epoxy-based photoresist) microcontainers were fabricated 
through two steps of photolithography to define the base and the 
walls (Fig. 4). This resulted in microcontainers with inner diameter 
of 223 µm (Fig. 1). Silicon wafers supporting the microcontainers 
were cut into squares of 12.8 x 12.8 mm2  resulting in 25 x 25 
microcontainers with a pitch of 450 µm (Fig. 5)2. 
 
 
 
Preparation of the amorphous sodium salt of furosemide3 
 
 
Filling of microcontainers with ASSF 
 
Powder drug distribution 
 
Removal with air gun 
The microcontainers were filled with ASSF by first distributing the 
powder onto the squares with microcontainers and subsequently, 
removing the powder in between the microcontainers with an air 
gun4. 
 
Coating of drug-filled microcontainers 
The drug-filled microcontainers were spray coated with a lid of 
either the pH-sensitive polymer, Eudragit® L100 or the 
mucoadhesive polymer, chitosan.  
 
 
In situ intestinal perfusion studies 
In situ intestinal perfusion studies were performed in fasted rats 
with a weight of approximately 200 g (Fig. 6)5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The coated, ASSF-filled microcontainers were dosed with 10 mL 
of phosphate buffer at pH 6.5 directly to the small intestine. As 
controls, a solution of furosemide in phosphate buffer, as well as 
empty microcontainers, were dosed. Blood samples (200 µL) were 
drawn every 5 min for 30 min. After the 30 min, the small intestine 
was harvested from the rat and imaged under a UV and 
fluorescence microscope.  
 
 
 
 
 
Oral bioavailability study in rats 
 
 
RESULTS 
 
Preparation of the ASSF 
 ASSF was successfully prepared by spray 
drying. The drug form showed promising in vitro 
properties in terms of high solubility and 
increased dissolution rate at pH 6.54. 
Filling of microcontainers with drug powder 
Loading of drug powder into the microcontainers was shown to 
be a very useful method for quickly filling the microcontainers 
while avoiding deposition of drug powder in between the 
microcontainers (Fig. 7). Moreover, the method can be utilised for 
all type of drugs.  
 
Fig. 7: A microcontainer after 
drug filling  
Fig. 8: A microcontainer after drug 
filling and spray coating with a 
polymer layer 
 
Coating of drug-filled microcontainers  
Fig. 8 shows a drug-filled SU-8 microcontainer coated with either 
Eudragit® L100 or chitosan. The thickness of the polymer layer was  
in both cases measured to be approximately 10 µm. 
 
In situ intestinal perfusion studies 
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CONCLUSION 
 
•  SU-8 microcontainers with inner diameter of 223 µm were 
fabricated  
• Microcontainers were filled with powder drug using a fast and 
widely-applicable method. 
•  The microcontainers interacted with the intestinal mucus layer  
• In rats ASSF in microcontainers exhibited a oral bioavailability of 
220% compared to capsules filled with ASSF 
 
• Microcontainers are proposed as a promising oral drug 
delivery system 
Oral bioavailability study in rats 
 
 
 
 
Fig. 10: Plasma furosemide concentrations 
after dosing of microcontainers filled with 
ASSF, coated with Eudragit® L100 and filled 
into capsules and ASSF dosed in capsules 
with Eudragit® coating after oral dosing to 
rats 
Eudragit coated 
microcontainers 
(Mean±SEM) 
Eudragit coated capsules 
(Mean±SEM) 
 
Tmax (min) 34.2±9.7 48.0±7.3 
Cmax (µg/mL) 1.9±0.48 1.7±0.68 
AUC0-180 min 179.6±33.3 152.2±39.2 
AUC0-1440 min 1696.4±299.7 326.1±55.0 
Relative bioavailability (%) 220.2±43.2 - 
After the oral dosing of the rats with either ASSF-filled 
microcontainers or ASSF filled into capsules, the plasma 
concentrations were initially similar, but the microcontainers 
exhibited a prolonged release of ASSF (Fig. 10) resulting in a 
bioavailability of 220% compared to the drug-filled capsules 
(Table 1).  
Fig. 6:  The set-up for the in situ intestinal perfusion studies in rats 
 
The ASSF-filled microcontainers were coated with Eudragit® L100 
and filled into capsules (size 9). As control ASSF was filled into 
capsules and subsequently, coated with Eudragit® L100 were 
used. The capsules were dosed orally to rats (~300 g) and 10 
blood samples were taken during 24h. 
 
Analysis of ASSF in the plasma samples: 
Rat plasma 
after oral 
dosing  
Plasma and 
acetonitrile 
centrifuged  
Supernatant Analyses by 
LC-MS 
Fig. 4:Scematic of the fabrication process of SU-8 
microcontainers 
A) B) C)
Fig. 9: Interaction of microcontainers with the intestinal mucus following in situ 
intestinal perfusion studies. Microcontainers were filled with ASSF and coated with a lid 
of A) Eudragit® L100 and B) chitosan. C) empty microcontainers without drug and 
coating 
 
The microscope images of the small intestine after the perfusion 
studies showed that the microcontainers interacted with the 
mucus in the small intestine, and the microcontainers were 
engulfed by the intestinal mucus (Fig. 9). By these qualitative 
results, it was observed that also without coating, the 
microcontainers interacted with the intestinal mucus (Fig. 9C).   
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Table 1: Noncompartmental pharmacokinetic parameters of ASSF following oral 
administration to rats 
